Nurse's perspective on PARP inhibitors and personalised medicine in prostate cancer
Nurse's perspective on PARP inhibitors and personalised medicine in prostate cancer
TALAPRO-1: phase II study of talazoparib in patients with DNA damage repair alterations and mCRPC
OncoAlert and ecancer weekly roundup for February 07 - 13, 2021
OncoAlert and ecancer weekly roundup for February 01 - 06, 2021
Latest in EGFR-positive NSCLC with exon 20 insertion mutations
WCLC 2020 overview
Emergence of PARP inhibitors in prostate cancer
OncoAlert and ecancer weekly roundup for January 25 - 31, 2021
Role of PARP inhibitors in treating advanced prostate cancer
WCLC 2020: Updates from the CHRYSALIS trial and what it means for patients with NSCLC
New data from rare EGFR alterations in NSCLC from WCLC 2020
A new way of thinking on the origin of breast cancer and how early breast cancer should be treated